{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T19:15:03Z","timestamp":1766171703747,"version":"3.48.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,16]],"date-time":"2025-11-16T00:00:00Z","timestamp":1763251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,16]],"date-time":"2025-11-16T00:00:00Z","timestamp":1763251200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Ophthalmol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Intraocular pressure (IOP) is a major clinical marker used to diagnose glaucoma and monitor its treatment. Marijuana use can confound IOP measurements by temporarily lowering the IOP, potentially leading to missed diagnoses of glaucoma or a false sense of effective treatment. Therefore, factors that may affect diagnosis or treatment of glaucoma need to be characterized and considered. We aim to assess the prevalence of cannabis use among patients presenting for an eye examination.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A survey was administered to 134 patients arriving for their regular ophthalmic appointments, from Oct 2022 to Jan 2023 and Jul 2024\u2013Aug 2024 in four eye clinics at the University of Minnesota (UMN).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among study patients, 15.7% reported recent use of marijuana (&lt;\u20091\u00a0month), 8.2% described themselves as regular users, and 4.5% of patients reported using it every day. Just under half (44.2%) of glaucoma patients indicated they were interested in using marijuana for their glaucoma. Patients that used marijuana less than 24\u00a0h from their eye exam were significantly more likely to know that marijuana decreases intraocular pressure (IOP) (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.02). Beliefs that marijuana is effective (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.016), lowers IOP (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.011), and has fewer side effects than glaucoma medications (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.014) were predictive of interest in marijuana use. In contrast, beliefs that marijuana has negative physical (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.041) and mental (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.003) health effects were predictive of disinterest in use.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>These findings indicate need for increased patient screening for recent marijuana use so ophthalmologists may contextually assess IOP and educate patients on marijuana\u2019s effects on the diagnosis and treatment of glaucoma.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10792-025-03846-2","type":"journal-article","created":{"date-parts":[[2025,11,16]],"date-time":"2025-11-16T18:10:49Z","timestamp":1763316649000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["An assessment of the prevalence of cannabis use in eye clinic patients and its implications on glaucoma diagnosis and management"],"prefix":"10.1007","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5273-9320","authenticated-orcid":false,"given":"Andrew J.","family":"Adamek","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Musse A.","family":"Hussein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iya","family":"Abdulkarim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Orengo-Nania","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huda","family":"Sheheitli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,16]]},"reference":[{"key":"3846_CR1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1136\/bjo.77.1.17","volume":"77","author":"M Coffey","year":"1993","unstructured":"Coffey M, Reidy A, Wormald R et al (1993) Prevalence of glaucoma in the west of Ireland. Br J Ophthalmol 77:17\u201321. https:\/\/doi.org\/10.1136\/bjo.77.1.17","journal-title":"Br J Ophthalmol"},{"key":"3846_CR2","first-page":"2251","volume":"40","author":"S Fraser","year":"1999","unstructured":"Fraser S, Bunce C, Wormald R (1999) Risk factors for late presentation in chronic glaucoma. Invest Ophthalmol Vis Sci 40:2251\u20132257","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"4","key":"3846_CR3","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0267582","volume":"17","author":"BK Belete","year":"2022","unstructured":"Belete BK, Assefa NL, Assem AS, Ayele FA (2022) Determinants for late presentation of glaucoma among adult glaucomatous patients in University of Gondar Comprehensive Specialized Hospital. Case-control study. PLoS ONE 17(4):e0267582. https:\/\/doi.org\/10.1371\/journal.pone.0267582","journal-title":"PLoS ONE"},{"issue":"6","key":"3846_CR4","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1016\/j.ajo.2014.08.023","volume":"158","author":"Y Shaikh","year":"2014","unstructured":"Shaikh Y, Yu F, Coleman AL (2014) Burden of undetected and untreated glaucoma in the United States. Am J Ophthalmol 158(6):1121-1129.e1. https:\/\/doi.org\/10.1016\/j.ajo.2014.08.023","journal-title":"Am J Ophthalmol"},{"key":"3846_CR5","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1159\/000348736","volume":"50","author":"P Bettin","year":"2013","unstructured":"Bettin P, Di Matteo F (2013) Glaucoma: present challenges and future trends. Ophthalmic Res 50:197\u2013208. https:\/\/doi.org\/10.1159\/000348736","journal-title":"Ophthalmic Res"},{"key":"3846_CR6","first-page":"741","volume":"41","author":"LA Kerrigan-Baumrind","year":"2000","unstructured":"Kerrigan-Baumrind LA, Quigley HA, Pease ME et al (2000) Number of ganglion cells in glaucoma eyes compared with threshold visual field tests in the same persons. Invest Ophthalmol Vis Sci 41:741\u2013748","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"3846_CR7","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.124.1.12","author":"PP Lee","year":"2006","unstructured":"Lee PP, Walt JG, Doyle JJ et al (2006) A multicenter, retrospective pilot study of resource use and costs associated with severity of disease in glaucoma. Arch Ophthalmol. https:\/\/doi.org\/10.1001\/archopht.124.1.12","journal-title":"Arch Ophthalmol"},{"issue":"6","key":"3846_CR8","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/j.mayocpiqo.2022.09.007","volume":"6","author":"IV Wagner","year":"2022","unstructured":"Wagner IV, Stewart MW, Dorairaj SK (2022) Updates on the diagnosis and management of glaucoma. Mayo Clin Proc Innov Qual Outcomes 6(6):618\u2013635. https:\/\/doi.org\/10.1016\/j.mayocpiqo.2022.09.007","journal-title":"Mayo Clin Proc Innov Qual Outcomes"},{"key":"3846_CR9","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1016\/j.survophthal.2008.08.006","volume":"53","author":"AL Coleman","year":"2008","unstructured":"Coleman AL, Miglior S (2008) Risk factors for glaucoma onset and progression. Surv Ophthalmol 53:S3\u2013S10. https:\/\/doi.org\/10.1016\/j.survophthal.2008.08.006","journal-title":"Surv Ophthalmol"},{"issue":"3","key":"3846_CR10","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1001\/jamaophthalmol.2016.5318","volume":"135","author":"H Ho","year":"2017","unstructured":"Ho H, Shi Y, Chua J, Tham Y-C, Lim SH, Aung T, Wong TY, Cheng C-Y (2017) Association of systemic medication use with intraocular pressure in a multiethnic Asian population. JAMA Ophthalmol 135(3):196. https:\/\/doi.org\/10.1001\/jamaophthalmol.2016.5318","journal-title":"JAMA Ophthalmol"},{"key":"3846_CR11","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/978-1-4613-4286-1_5","volume-title":"The therapeutic potential of marihuana","author":"RS Hepler","year":"1976","unstructured":"Hepler RS, Petrus RJ (1976) Experiences with administration of marihuana to glaucoma patients. The therapeutic potential of marihuana. Springer US, pp 63\u201375. https:\/\/doi.org\/10.1007\/978-1-4613-4286-1_5"},{"key":"3846_CR12","doi-asserted-by":"publisher","first-page":"736792","DOI":"10.3389\/FMED.2021.736792","volume":"8","author":"S Mosaed","year":"2022","unstructured":"Mosaed S, Smith AK, Liu JHK et al (2022) The relationship between plasma tetrahydrocannabinol levels and intraocular pressure in healthy adult subjects. Front Med (Lausanne) 8:736792. https:\/\/doi.org\/10.3389\/FMED.2021.736792","journal-title":"Front Med (Lausanne)"},{"key":"3846_CR13","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/S0161-6420(80)35258-5","volume":"87","author":"JC Merritt","year":"1980","unstructured":"Merritt JC, Crawford WJ, Alexander PC et al (1980) Effect of marihuana on intraocular and blood pressure in glaucoma. Ophthalmology 87:222\u2013228. https:\/\/doi.org\/10.1016\/S0161-6420(80)35258-5","journal-title":"Ophthalmology"},{"issue":"5","key":"3846_CR14","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1097\/01.IJG.0000212260.04488.60","volume":"15","author":"I Tomida","year":"2006","unstructured":"Tomida I, Azuara-Blanco A, House H, Flint M, Pertwee RG, Robson PJ (2006) Effect of sublingual application of cannabinoids on intraocular pressure: a pilot study. J Glaucoma 15(5):349\u2013353. https:\/\/doi.org\/10.1097\/01.IJG.0000212260.04488.60","journal-title":"J Glaucoma"},{"key":"3846_CR15","unstructured":"Skye Bioscience (2024) Skye bioscience completes enrollment of phase 2a clinical trial of SBI-100 ophthalmic emulsion in glaucoma and ocular hypertension\u202f:: Skye Bioscience, Inc. (SKYE). In: Skye Bioscience. https:\/\/ir.skyebioscience.com\/news-releases\/detail\/189\/skye-bioscience-completes-enrollment-of-phase-2a-clinical-trial-of-sbi-100-ophthalmic-emulsion-in-glaucoma-and-ocular-hypertension. Accessed 11 Oct 2025"},{"key":"3846_CR16","unstructured":"Skye Bioscience Inc (2024) Phase 2, placebo-controlled, study assessing the safety and ocular efficacy of SBI-100 ophthalmic emulsion in patients with elevated eye pressure (NCT06144918). ClinicalTrials.gov"},{"key":"3846_CR17","doi-asserted-by":"publisher","first-page":"5904","DOI":"10.1167\/IOVS.18-24838","volume":"59","author":"S Miller","year":"2018","unstructured":"Miller S, Daily L, Leishman E et al (2018) \u03949-tetrahydrocannabinol and cannabidiol differentially regulate intraocular pressure. Invest Ophthalmol Vis Sci 59:5904. https:\/\/doi.org\/10.1167\/IOVS.18-24838","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"3846_CR18","doi-asserted-by":"publisher","first-page":"2930","DOI":"10.1167\/IOVS.16-21330","volume":"58","author":"S Miller","year":"2017","unstructured":"Miller S, Hu SSJ, Leishman E et al (2017) A GPR119 signaling system in the murine eye regulates intraocular pressure in a sex-dependent manner. Invest Ophthalmol Vis Sci 58:2930. https:\/\/doi.org\/10.1167\/IOVS.16-21330","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"3846_CR19","first-page":"2442","volume":"40","author":"AJ Straiker","year":"1999","unstructured":"Straiker AJ, Maguire G, Mackie K, Lindsey J (1999) Localization of cannabinoid CB1 receptors in the human anterior eye and retina. Invest Ophthalmol Vis Sci 40:2442\u20132448","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"3846_CR20","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1089\/JOP.1990.6.259","volume":"6","author":"BK Colasanti","year":"1990","unstructured":"Colasanti BK (1990) A comparison of the ocular and central effects of delta 9-tetrahydrocannabinol and cannabigerol. J Ocul Pharmacol 6:259\u2013269. https:\/\/doi.org\/10.1089\/JOP.1990.6.259","journal-title":"J Ocul Pharmacol"},{"key":"3846_CR21","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/SJ.BJP.0707442","volume":"153","author":"RG Pertwee","year":"2007","unstructured":"Pertwee RG (2007) The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: \u03949-tetrahydrocannabinol, cannabidiol and \u03949-tetrahydrocannabivarin. Br J Pharmacol 153:199. https:\/\/doi.org\/10.1038\/SJ.BJP.0707442","journal-title":"Br J Pharmacol"},{"key":"3846_CR22","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1136\/BJO.2003.032250","volume":"88","author":"I Tomida","year":"2004","unstructured":"Tomida I, Perlwee RG, Azuara-Blanco A (2004) Cannabinoids and glaucoma. Br J Ophthalmol 88:708. https:\/\/doi.org\/10.1136\/BJO.2003.032250","journal-title":"Br J Ophthalmol"},{"key":"3846_CR23","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1021\/ACSPTSCI.4C00583","volume":"8","author":"L Pk","year":"2025","unstructured":"Pk L, Pawar RS, Katare YK, Sudheesh MS (2025) Cannabinoids as multitarget drugs for the treatment of autoimmunity in glaucoma. ACS Pharmacol Transl Sci 8:932\u2013950. https:\/\/doi.org\/10.1021\/ACSPTSCI.4C00583","journal-title":"ACS Pharmacol Transl Sci"},{"key":"3846_CR24","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1001\/ARCHOPHT.121.1.87","volume":"121","author":"FY Chien","year":"2003","unstructured":"Chien FY, Wang RF, Mittag TW, Podos SM (2003) Effect of WIN 55212\u20132, a cannabinoid receptor agonist, on aqueous humor dynamics in monkeys. Arch Ophthalmol 121:87\u201390. https:\/\/doi.org\/10.1001\/ARCHOPHT.121.1.87","journal-title":"Arch Ophthalmol"},{"key":"3846_CR25","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/S0169-328X(98)00105-3","volume":"58","author":"A Porcella","year":"1998","unstructured":"Porcella A, Casellas P, Gessa GL, Pani L (1998) Cannabinoid receptor CB1 mRNA is highly expressed in the rat ciliary body: implications for the antiglaucoma properties of marihuana. Mol Brain Res 58:240\u2013245. https:\/\/doi.org\/10.1016\/S0169-328X(98)00105-3","journal-title":"Mol Brain Res"},{"key":"3846_CR26","unstructured":"AAO Complementary Therapy Task Force HC for QEC (2014) Marijuana in the Treatment of Glaucoma CTA\u20132014"},{"key":"3846_CR27","unstructured":"NCSL Editors (2025) State Medical Cannabis Laws. In: NSCL. https:\/\/www.ncsl.org\/health\/state-medical-cannabis-laws. Accessed 1 Sep 2025"},{"key":"3846_CR28","unstructured":"CDC (2024) State Medical Cannabis Laws. In: Cannabis and Public Health. https:\/\/www.cdc.gov\/cannabis\/about\/state-medical-cannabis-laws.html. Accessed 17 Dec 2024"},{"key":"3846_CR29","unstructured":"Walker T (2023) House passes bill to legalize recreational cannabis, sends it to Senate. In: Minnesota House of Representatives. https:\/\/www.house.mn.gov\/sessiondaily\/Story\/17948. Accessed 17 Dec 2024"},{"key":"3846_CR30","doi-asserted-by":"publisher","first-page":"E2136571","DOI":"10.1001\/jamanetworkopen.2021.36571","volume":"4","author":"AM Jeffers","year":"2021","unstructured":"Jeffers AM, Glantz S, Byers A, Keyhani S (2021) Sociodemographic characteristics associated with and prevalence and frequency of cannabis use among adults in the US. JAMA Netw Open 4:E2136571. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.36571","journal-title":"JAMA Netw Open"},{"issue":"5","key":"3846_CR31","doi-asserted-by":"publisher","first-page":"e219375","DOI":"10.1001\/jamanetworkopen.2021.9375","volume":"4","author":"TE Matson","year":"2021","unstructured":"Matson TE, Carrell DS, Bobb JF, Cronkite DJ, Oliver MM, Luce C, Lapham GT (2021) Prevalence of medical cannabis use and associated health conditions documented in electronic health records among primary care patients in Washington State. JAMA Netw Open 4(5):e219375\u2013e219375","journal-title":"JAMA Netw Open"},{"key":"3846_CR32","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/j.amepre.2023.03.005","volume":"65","author":"TG Rhee","year":"2023","unstructured":"Rhee TG, Rosenheck RA (2023) Increasing use of cannabis for medical purposes among U.S. residents, 2013\u20132020. Am J Prev Med 65:528\u2013533. https:\/\/doi.org\/10.1016\/j.amepre.2023.03.005","journal-title":"Am J Prev Med"},{"key":"3846_CR33","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/S0161-6420(01)01030-2","volume":"109","author":"DJ Rhee","year":"2002","unstructured":"Rhee DJ, Spaeth GL, Myers JS et al (2002) Prevalence of the use of complementary and alternative medicine for glaucoma. Ophthalmology 109:438\u2013443. https:\/\/doi.org\/10.1016\/S0161-6420(01)01030-2","journal-title":"Ophthalmology"},{"key":"3846_CR34","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1001\/jamaophthalmol.2015.5209","volume":"134","author":"DA Belyea","year":"2016","unstructured":"Belyea DA, Alhabshan R, del Rio-Gonzalez AM et al (2016) Marijuana use among patients with glaucoma in a city with legalized medical marijuana use. JAMA Ophthalmol 134:259. https:\/\/doi.org\/10.1001\/jamaophthalmol.2015.5209","journal-title":"JAMA Ophthalmol"},{"key":"3846_CR35","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.ogla.2020.06.009","volume":"3","author":"EW Weldy","year":"2020","unstructured":"Weldy EW, Stanley J, Koduri VA et al (2020) Perceptions of marijuana use for glaucoma from patients, cannabis retailers, and glaucoma specialists. Ophthalmol Glaucoma 3:453\u2013459. https:\/\/doi.org\/10.1016\/j.ogla.2020.06.009","journal-title":"Ophthalmol Glaucoma"},{"key":"3846_CR36","unstructured":"University of Minnesota Institutional Review Board (2022) SOCIAL PROTOCOL (HRP-580)"},{"issue":"2","key":"3846_CR37","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","volume":"42","author":"PA Harris","year":"2009","unstructured":"Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG (2009) Research electronic data capture (REDCap)-a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 42(2):377\u2013381. https:\/\/doi.org\/10.1016\/j.jbi.2008.08.010","journal-title":"J Biomed Inform"},{"key":"3846_CR38","doi-asserted-by":"publisher","first-page":"103208","DOI":"10.1016\/j.jbi.2019.103208","volume":"95","author":"PA Harris","year":"2019","unstructured":"Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O\u2019Neal L, McLeod L, Delacqua G, Delacqua F, Kirby J, Duda SN (2019) The REDCap consortium: building an international community of software platform partners. J Biomed Inform 95:103208. https:\/\/doi.org\/10.1016\/j.jbi.2019.103208","journal-title":"J Biomed Inform"},{"key":"3846_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2015\/435606","volume":"2015","author":"FA Wilson","year":"2015","unstructured":"Wilson FA, Stimpson JP, Wang Y (2015) Inconsistencies exist in national estimates of eye care services utilization in the United States. J Ophthalmol 2015:1\u20134. https:\/\/doi.org\/10.1155\/2015\/435606","journal-title":"J Ophthalmol"},{"key":"3846_CR40","doi-asserted-by":"publisher","DOI":"10.1111\/add.14031","author":"WC Kerr","year":"2018","unstructured":"Kerr WC, Lui C, Ye Y (2018) Trends and age, period and cohort effects for marijuana use prevalence in the 1984\u20132015 US National Alcohol Surveys. Addiction. https:\/\/doi.org\/10.1111\/add.14031","journal-title":"Addiction"},{"key":"3846_CR41","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/s0084-392x(08)70053-4","volume":"7","author":"RL Fellman","year":"2006","unstructured":"Fellman RL (2006) A multicenter, retrospective pilot study of resource use and costs associated with severity of disease in glaucoma: commentary. Evid Based Ophthalmol 7:146\u2013147. https:\/\/doi.org\/10.1016\/s0084-392x(08)70053-4","journal-title":"Evid Based Ophthalmol"},{"issue":"1","key":"3846_CR42","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1001\/ARCHOPHT.121.1.48","volume":"121","author":"MC Leske","year":"2003","unstructured":"Leske MC, Heijl A, Hussein M, Bengtsson B, Hyman L, Komaroff E, Early Manifest Glaucoma Trial Group (2003) Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial. Arch Ophthalmol 121(1):48\u201356. https:\/\/doi.org\/10.1001\/ARCHOPHT.121.1.48","journal-title":"Arch Ophthalmol"},{"key":"3846_CR43","unstructured":"United States Census Bureau (2022) Quick Facts. https:\/\/www.census.gov\/quickfacts\/MN"},{"key":"3846_CR44","unstructured":"38 U.S. Code \u00a7 7332\u2014Confidentiality of certain medical records | U.S. Code | US Law | LII \/ Legal Information Institute. https:\/\/www.law.cornell.edu\/uscode\/text\/38\/7332. Accessed 11 Oct 2025"}],"container-title":["International Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-025-03846-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10792-025-03846-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-025-03846-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T19:01:59Z","timestamp":1766170919000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10792-025-03846-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,16]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3846"],"URL":"https:\/\/doi.org\/10.1007\/s10792-025-03846-2","relation":{},"ISSN":["1573-2630"],"issn-type":[{"type":"electronic","value":"1573-2630"}],"subject":[],"published":{"date-parts":[[2025,11,16]]},"assertion":[{"value":"17 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}}],"article-number":"484"}}